hepatocellular carcinoma
Conditions
Interventions
Sponsors
Mengchao Hepatobiliary Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Hepatitis B patient (1) Aged 18 (inclusive) to 70 years old (inclusive), male or female; (2) Previously diagnosed as chronic HBV infection (ie, HBsAg positive = 6 months). 2. Patients with chronic cirrhosis (1) Aged 18 (inclusive) to 75 years old (inclusive), male or female; (2) The results of the examination within the last six months are according with the diagnostic criteria for cirrhosis as specified in this study (see Section 7 - Variable Definitions for details). 3. HCC patients: (1) Aged 18 (inclusive) to 75 years old (inclusive), male or female; (2) The results of the examination within the last six months are according with the diagnostic criteria for HCC as specified in this study; (3) Acceptable standard clinical treatment plan for liver cancer such as surgery, TACE or targeted therapy.
Exclusion criteria
Exclusion criteria: 1. Hepatitis B patients Identify other causes of liver disease, including but not limited to: (1) autoimmune liver disease (PBC, PSC, AIH, IgG4-related liver disease, etc.); (2) Inherited metabolic liver disease (hepatic nucleus degeneration, etc.); (3) Other clear chronic liver diseases (schistosomiasis, liver disease, etc.): 1) Patients with HCV, HDV, HEV, HIV infection; 2) Previously diagnosed active tuberculosis; 3) Diagnosis of malignant tumors before or during hospitalization, including but not limited to hepatocellular carcinoma; 4) Patients who have received allogeneic blood transfusion or cell therapy within 1 year; 5) pregnant women; 6) Other liver diseases of unknown cause. 2. Patients with chronic cirrhosis: (1) Current Child-Pugh patients with grade C; (2) Previous examination results suggest patients with cirrhosis induced by other causes: 1) Inherited metabolic liver disease (hepatolenticular degeneration, etc.); 2) Clear chronic liver disease (schistosomiasis, liver disease, etc.). HIV-Ab+; Previously diagnosed active tuberculosis; Diagnosis of malignant tumors before or during hospitalization, including but not limited to hepatocellular carcinoma; Patients who have received allogeneic blood transfusion or cell therapy within 1 year; pregnant women; 3. HCC patients: (1) Current Child-Pugh patients with grade C; (2) The results of previous examinations indicate HCC patients induced by other causes: 1) Inherited metabolic liver disease (hepatolenticular degeneration, etc.); 2) Clear chronic liver disease (schistosomiasis, liver disease, etc.). HIV-Ab+; Previously diagnosed active tuberculosis; Diagnosis of other malignant tumors, non-primary hepatocellular carcinoma, etc. before admission or during hospitalization; Patients who have received allogeneic blood transfusion or cell therapy within 1 year; pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA burden; | — |
Countries
China
Contacts
Public ContactXiaolong Liu
Mengchao Hepatobiliary Hospital of Fujian Medical University
Outcome results
None listed